论文部分内容阅读
PURPOSE: To estimate the frequency of documentation of glaucoma medications by primary care physicians. DESIGN: Cross-sectional, observational study. METHODS: The general medical records of 100 patients of one glaucoma specialistwere reviewed. We recorded whether the mention of eyedrops appeared in the medical recor d. RESULTS: The median number of glaucoma medications used was 2.5 (range 1 to 5 ). Fifty-five (55%, 95%confidence interval: 45%-65%) of the medical record s of the primary physicians mentioned eyedrops. α-Agonists were statistically less frequently documented (13%) in the general medical record than β-adrener gic blockers (47%)-and prostaglandins (44%). CONCLUSION: Almost half of the c harts of these primary physicians had no documentation of any eyedrop use by the ir patients with glaucoma. An important step in reducing drug-induced side effects and interactions with other medications would be better recognition by primary physicians of the ophthalmic drugs used by their patients.
PURPOSE: To estimate the frequency of documentation of glaucoma medications by primary care physicians. DESIGN: Cross-sectional, observational study. METHODS: The general medical records of 100 patients of one glaucoma specialistwere reviewed. We recorded whether the mention of eyedrops appeared in the the RESULTS: The median number of glaucoma medications used was 2.5 (range 1 to 5). Fifty-five (55%, 95% confidence interval: 45% -65%) of the medical record s of the primary physicians mentioned α-Agonists were statistically less frequently documented (13%) in the general medical record than β-adrener gic blockers (47%) - and prostaglandins (44%). CONCLUSION: Almost half of the c harts of these primary physicians had no documentation of any eyedrop use by the ir patients with glaucoma. An important step in reducing drug-induced side effects and interactions with other medications would be better recognition by primary physicians of the ophthalmic drugs used by thei r patients.